Novavax Inc.

Novavax Inc. is a biotechnology company that engages in the discovery, development, and commercialization of recombinant vaccines to protect against serious infectious diseases. It specializes in protein-based vaccine platforms, including its proprietary Matrix-M adjuvant technology, which enhances immune responses. The company focuses on vaccines for respiratory diseases, such as its Nuvaxovid COVID-19 vaccine, and advances a pipeline targeting influenza, combination COVID-influenza, and other pathogens. Novavax Inc. operates through strategic partnerships with global pharmaceutical leaders like Pfizer and Sanofi for manufacturing, distribution, and milestone-based collaborations, enabling broader market reach in the United States, Europe, and internationally. Its recombinant nanoparticle vaccine approach distinguishes it in the health technology sector, emphasizing innovative solutions for pandemic preparedness and routine immunization needs. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax Inc. plays a key role in the biotechnology industry by addressing unmet needs in infectious disease prevention.